NCT04895735 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04895735
Title	Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Mayo Clinic
Indications	salivary gland cancer
Therapies	Pembrolizumab + Pemetrexed Disodium
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Mayo Clinic in Arizona		Scottsdale	Arizona	85259	United States	Details
Mayo Clinic in Rochester		Rochester	Minnesota	55905	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04895735Clinical Trial Detail